LFLukas Farbiak

Lukas Farbiak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lukas Farbiak has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel John Siegwart

    Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    11 shared publications
  • Sumanta Chatterjee

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    7 shared publications
  • Xizhen Lian

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    6 shared publications
  • Xu Wang

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, USA

    6 shared publications
  • Amogh Vaidya

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    5 shared publications
  • Yehui Sun

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    5 shared publications

Latest Publications

  • Open Access

    Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration

    by Zeru Tian, Xu Wang, Alexis Pacheco Benitez, Erick Guerrero, Yaou Duan, Jingwen Wei, Lukas Farbiak, Daniel J. Siegwart

    The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.


  • Open Access

    ‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing

    by Zeru Tian, Xu Wang, Sumanta Chatterjee, William Miller, Erick Guerrero, Yun-Chieh Sung, Alexis Pacheco Benitez, Sean Dilliard, Xiaoyan Bian, Amogh Vaidya, et al.

    Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR–Cas9 genome editors to lungs with minimal side effects. Empirical analyses revealed structure–activity relationships, with top-performing LuT lipids possessing a unique ‘tripod-like’ structure consisting of a quaternary amine head, three long alkyl chains as legs and a short chain as a handle. LuT lipids improved endosomal escape, cargo release and endogenous targeting via adsorption of plasma proteins. Lead 1A7B13 LNPs showed a 25.5-fold improvement in mRNA delivery and a 9.2-fold increase in CRISPR–Cas9 gene-editing efficiency compared to benchmark DOTAP SORT LNPs, achieving over 90% selectivity to the lungs. 1A7B13 LNPs effectively delivered IL-10 mRNA in a therapeutic model of acute lung injury. This study reveals the relationship between lipid structure and lung-targeting activity, enriching the toolkit for lung-specific carriers.


  • Top Cited Papers
    Open Access

    Multiplexed lipid nanoparticle barcoding reveals tissue-dynamic kinetic insights and enriched cellular tropism in hepatic zones

    by Stephen T. Moore, Xizhen Lian, Amogh Vaidya, Sumanta Chatterjee, Julien Santelli, Yehui Sun, Lukas Farbiak, Hao Zhu, Daniel J. Siegwart

    Lipid nanoparticles (LNPs) efficiently deliver nucleic acids to cells in vivo and facilitate clinical applications including RNA-based vaccines and therapies. Discovery and optimization of LNPs remain challenging due to the complexity of input variables and low throughput workflows. To accelerate these processes, we report a broadly compatible barcoded Cre recombinase mRNA barcode platform that enables multiplexed LNP tracking in vivo in tdTomato reporter mice. We evaluate accumulation and degradation kinetics of mRNA encapsulated in Selective Organ Targeting (SORT) LNPs in the liver, lung, and spleen, and show that functional protein activity is associated with rapid organ enrichment. We further demonstrate how barcode multiplexing can streamline systematic kinetic studies, distinguish nanoparticles with distinct biological outcomes, and differentiate subtle, yet important, variations within a series of similar formulations. Finally, we use barcoding to identify and characterize nanoparticles with hepatic zonal bias and previously overlooked extrahepatic tropism. This approach could accelerate high resolution characterization of nanoparticles with desirable properties, enable large-scale systematic studies of diverse LNPs, and provide insights into optimizable parameters of LNP-mRNA delivery.


  • Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells

    by Yujin Kim, Sumanta Chatterjee, Ava L. Robertson, Erick D. Guerrero, Amogh Vaidya, Xu Wang, Sang M. Lee, Jingwen Wei, William E. Miller, Lukas Farbiak, et al.

    Lipid nanoparticle (LNP) delivery of mRNA to specific cell types is a necessary task for the development of safe and effective medicines. LNP delivery to the liver is largely driven by the binding of serum ApoE to the LNP surface, followed by subsequent uptake in LDL receptor (LDL-R)-expressing hepatocytes, thereby reducing their utility in nonhepatocyte liver diseases. Herein, we developed an active targeting strategy to overcome this limitation by incorporating mannose-conjugated cholesterol into LNPs. Since cholesterol comprises about half of all molecules in LNPs, we reasoned that it could serve as a scaffold for active targeting. Mannosylated LNPs enhance uptake into liver sinusoidal endothelial cells (LSECs) and Kupffer cells over hepatocytes following intravenous administration in mice. This process correlated with the expression of mannose receptors (CD206) in LSECs and Kupffer cells, where significantly greater LNP uptake and functional mRNA delivery occurred in CD206+ cells. Higher activity and selectivity could be endowed by reducing the hydrophobic acyl chain length in poly(ethylene glycol) (PEG) lipids to induce faster PEG shedding in systemic circulation and increase LNP surface-accessible mannose, thereby increasing binding interactions with mannose receptors on CD206+ cells and subsequent LNP uptake. The results establish that cholesterol can be employed as a ligand carrier in LNPs for enriching mRNA delivery to specific cells in vivo. We anticipate that this general strategy of cholesterol modification can be extended to other ligands and cell types in the future.


  • Reducing Complexity in Lipid Nanoparticles: Three-Component Zwitterionic Amino Lipids for Targeted Extrahepatic mRNA Delivery

    by Joshua J. Robinson, Di Zhang, Pratima Basak, Amogh Vaidya, Sumanta Chatterjee, Xiaoyan Bian, Minjeong Kim, Xizhen Lian, Yehui Sun, Erick Guerrero, et al.

    Simplicity and chemical expansion of lipid nanoparticles (LNPs) offer the potential for increased therapeutic benefit of mRNA vaccines and medicines. 3-Component Zwitterionic Amino Lipid (ZAL) LNPs offer simplicity and varied organ target scope, though there is a lack of chemical and formulation exploration with this class of lipids. Herein, we report the synthesis and evaluation of ZALs with improved biocompatibility, enhanced mRNA delivery efficacy, and extrahepatic organ-specific delivery through derivation at the secondary hydroxyl position with opivalate, chloride, bromide, and acetate. Evaluation of these novel ZAL molecules revealed organ-specific delivery trends, changes in delivery efficacy, and an engineering framework for chemically modifying lipid components that correlate with each specific chemical modification. Furthermore, the most efficacious ZAL derivative, which contains an acetate modification, displayed enhanced immune cell transfection in an organ-specific manner. This study provides a roadmap for reducing the complexity of LNPs by decreasing the number of lipid components in an LNP from the canonical 4 lipids to 3 lipids and expands the chemical scope of LNPs capable of mediating extrahepatic delivery.


  • Open Access

    Publisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics

    by Yufen Xiao, Xizhen Lian, Yehui Sun, Yun-Chieh Sung, Amogh Vaidya, Zexiang Chen, Ankit Gupta, Sumanta Chatterjee, Lining Zheng, Erick Guerrero, et al.


  • Top Cited Papers

    High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics

    by Yufen Xiao, Xizhen Lian, Yehui Sun, Yun-Chieh Sung, Amogh Vaidya, Zexiang Chen, Ankit Gupta, Sumanta Chatterjee, Lining Zheng, Erick Guerrero, et al.

    Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.


  • Open Access

    In situ production and secretion of proteins endow therapeutic benefit against psoriasiform dermatitis and melanoma

    by Qiang Cheng, Lukas Farbiak, Amogh Vaidya, Erick Guerrero, Eunice E. Lee, Elysha K. Rose, Xu Wang, Joshua Robinson, Sang M. Lee, Tuo Wei, et al.

    Genetic medicines have the potential to treat various diseases; however, certain ailments including inflammatory diseases and cancer would benefit from control over extracellular localization of therapeutic proteins. A critical gap therefore remains the need to develop and incorporate methodologies that allow for posttranslational control over expression dynamics, localization, and stability of nucleic acid–generated protein therapeutics. To address this, we explored how the body’s endogenous machinery controls protein localization through signal peptides (SPs), including how these motifs could be incorporated modularly into therapeutics. SPs serve as a virtual zip code for mRNA transcripts that direct the cell where to send completed proteins within the cell and the body. Utilizing this signaling biology, we incorporated secretory SP sequences upstream of mRNA transcripts coding for reporter, natural, and therapeutic proteins to induce secretion of the proteins into systemic circulation. SP sequences generated secretion of various engineered proteins into the bloodstream following intravenous, intramuscular, and subcutaneous SP mRNA delivery by lipid, polymer, and ionizable phospholipid delivery carriers. SP-engineered etanercept/TNF-α inhibitor proteins demonstrated therapeutic efficacy in an imiquimod-induced psoriasis model by reducing hyperkeratosis and inflammation. An SP-engineered anti-PD-L1 construct mediated mRNA encoded proteins with longer serum half-lives that reduced tumor burden and extended survival in MC38 and B16F10 cancer models. The modular nature of SP platform should enable intracellular and extracellular localization control of various functional proteins for diverse therapeutic applications.


  • Lipid Nanoparticle (LNP) Chemistry Can Endow Unique In Vivo RNA Delivery Fates within the Liver That Alter Therapeutic Outcomes in a Cancer Model

    by Lindsay T. Johnson, Di Zhang, Kejin Zhou, Sang M. Lee, Shuai Liu, Sean A. Dilliard, Lukas Farbiak, Sumanta Chatterjee, Yu-Hsuan Lin, Daniel J. Siegwart

    Within the field of lipid nanoparticles (LNPs) for RNA delivery, the focus has been mainly placed on organ level delivery, which can mask cellular level effects consequential to therapeutic applications. Here, we studied a pair of LNPs with similar physical properties and discovered how the chemistry of the ionizable amino lipid can control the endogenous LNP identity, affecting cellular uptake in the liver and altering therapeutic outcomes in a model of liver cancer. Although most LNPs accumulate in the liver after intravenous administration (suggesting that liver delivery is straightforward), we observed an unexpected behavior when comparing two similar LNP formulations (5A2-SC8 and 3A5-SC14 LNPs) that resulted in distinct RNA delivery within the organ. Despite both LNPs possessing similar physical properties, ability to silence gene expression in vitro, strong accumulation within the liver, and a shared pKa of 6.5, only 5A2-SC8 LNPs were able to functionally deliver RNA to hepatocytes. Factor VII (FVII) activity was reduced by 87%, with 5A2-SC8 LNPs carrying FVII siRNA (siFVII), while 3A5-SC14 LNPs carrying siFVII produced baseline FVII activity levels comparable to the nontreatment control at a dosage of 0.5 mg/kg. Protein corona analysis indicated that 5A2-SC8 LNPs bind apolipoprotein E (ApoE), which can drive LDL-R receptor-mediated endocytosis in hepatocytes. In contrast, the surface of 3A5-SC14 LNPs was enriched in albumin but depleted in ApoE, which likely led to Kupffer cell delivery and detargeting of hepatocytes. In an aggressive MYC-driven liver cancer model relevant to hepatocytes, 5A2-SC8 LNPs carrying let-7g miRNA were able to significantly extend survival up to 121 days. Since disease targets exist in an organ- and cell-specific manner, the clinical development of RNA LNP therapeutics will require an improved understanding of LNP cellular tropism within organs. The results from our work illustrate the importance of understanding the cellular localization of RNA delivery and incorporating further checkpoints when choosing nanoparticles beyond biochemical and physical characterization, as small changes in the chemical composition of LNPs can have an impact on both the biofate of LNPs and therapeutic outcomes.


  • Top Cited Papers

    Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

    by Di Zhang, Guoxun Wang, Xueliang Yu, Tuo Wei, Lukas Farbiak, Lindsay T. Johnson, Alan Mark Taylor, Jiazhu Xu, Yi Hong, Hao Zhu, et al.

    Genome editing holds great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR/Cas to solid tumours for efficient cancer therapy remains challenging. Here we targeted tumour tissue mechanics via a multiplexed dendrimer lipid nanoparticle (LNP) approach involving co-delivery of focal adhesion kinase (FAK) siRNA, Cas9 mRNA and sgRNA (siFAK + CRISPR-LNPs) to enable tumour delivery and enhance gene-editing efficacy. We show that gene editing was enhanced >10-fold in tumour spheroids due to increased cellular uptake and tumour penetration of nanoparticles mediated by FAK-knockdown. siFAK + CRISPR-PD-L1-LNPs reduced extracellular matrix stiffness and efficiently disrupted PD-L1 expression by CRISPR/Cas gene editing, which significantly inhibited tumour growth and metastasis in four mouse models of cancer. Overall, we provide evidence that modulating the stiffness of tumour tissue can enhance gene editing in tumours, which offers a new strategy for synergistic LNPs and other nanoparticle systems to treat cancer using gene editing.